Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05545410
Other study ID # APHP211541
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2022
Est. completion date November 2024

Study information

Verified date August 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Raluca PAIS, MD
Phone +33(0)1.42.16.55.45
Email raluca.pais@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective is to optimize MRI acquisition and image post-processing protocols in order to define the best compromise between short scan time and image quality (contrast between different tissues, spatial and temporal resolutions) high enough to accurately measure morphologic, hemodynamic and structural aortic biomarkers.


Description:

This Magnetic Resonance imaging study of the thoracic aorta aims to: 1- enhance patient comfort during the examination, shorten appointment waiting times and overall reduce MRI cost, and 2- provide a reliable diagnosis and risk assessment of aorta-related diseases occurring in hypertension, obesity or diabetes but also throughout normal aging. The impact of MRI acquisition innovations on the measurement of biomarkers that are extracted from image post-processing software and therein on disease characterization (normal values, severity thresholds, etc.) must be systematically reevaluated. More specifically, the investigators design image acquisition and automated image processing methods to reduce operator variability. This study will optimize thoracic aortic MRI acquisition sequences for the quantification of diagnostic-assisting biomarkers in a healthy population.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date November 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Subject aged between 20 and 35 or between 50 and 70 (limits included) - BMI < 30 kg/m² - Asymptomatic subject - Having given informed, free and written consent - Affiliated to a French social security scheme or entitled Exclusion Criteria: - Contraindication to MRI (claustrophobia, presence of a metallic foreign body) - Pregnant or breastfeeding woman - Known cardiac pathology - Personal cardiovascular history - Person deprived of liberty by court decision or benefiting from legal protection (under guardianship or curatorship) - Abuse of alcohol or narcotics - Subject under AME - Participation in another interventional research involving the human person or being in the exclusion period at the end of a previous research involving the human person

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRI calibration
Non-injected thoracic aorta MRI calibration

Locations

Country Name City State
France Hôpital de la Pitié Salpêtrière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Parametric measurement of thoracic aorta values of normal subjects Thoracic aorta values measured by MRI 24 months
Secondary Quantitative fibrosis within the aortic wall (%) 24 months
Secondary Quantitative fat within the aortic wall (%) 24 months
Secondary Quantitative periaortic fat (g and g/m², when indexed to BSA) 24 months
Secondary ROC metrics will be used to compare the various sequences (%) 24 months
Secondary Quantitative flow values within the different aortic segments and the main branches (mL) 24 months
Secondary Correlation coefficients will be estimated to assess the associations between novel and conventional biomarkers 24 months
Secondary Intra and inter-reproductibility of aortic measures will be assessed (intra-class correlation coefficients) 24 months
Secondary Intra and inter-reproductibility of aortic measures will be assessed (Bland and Altman metrics) 24 months
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1